Amgen, Allergan report Phase III data for Herceptin biosimilar

Amgen Inc. (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) said data from a Phase III study showed ABP 980, a biosimilar

Read the full 193 word article

User Sign In